Health

Merck ADC Drug Trial Success in Cancer Treatment

Updated 2026-10-26 15:35 UTC 1 source Positive

A Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut the risk of death by one-third for patients with advanced endometrial cancer.

Coverage timeline — 1 article

STAT News

STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer

A Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer

2026-10-26 15:30 UTC